List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Topic 364: SysMet: Integrative Systems Metabolomics

    SBC: OmicsCraft LLC            Topic: NCI

    Metabolomics plays an indispensable role in the growing systems biology approaches to identify reliable cancer biomarkers. Liquid chromatography coupled to mass spectrometry (LC-MS) and gas chromatography coupled to mass spectrometry (GC-MS) have been extensively used for high-throughput comparison of the levels of thousands of metabolites among biological samples. However, the potential values of ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Topic 380- QIDS: Using Radiomics to Impact Radiotherapy Treatment Planning- Moonshot

    SBC: HealthMyne, Inc.            Topic: NCI

    HealthMyne proposes developing a Clinical Decision Support tool to be used in the point-of-care workflow for the Radiation Oncologist that uses radiomic features that have evidence-based association to disease course and/or normal organ damage, in order to impact the treatment planning process. Phase 1 will focus on extraction, calculation, and validation of identified radiomic features for lung c ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Biomaterials for mRNA based cellular reprogramming

    SBC: Stem Pharm, Incorporated            Topic: 100

    Project Summary Abstract Induced pluripotent stem cells iPSCs hold great promise in the areas of disease modeling and regenerative medicine and as a result have unique commercial potential There are currently more than ongoing clinical trials in stem cell therapies including the first in human trial using human iPSC derived retinal pigment epithelial cells to treat ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Development of MTX for the Treatment of KRAS Mutant Colorectal Cancer

    SBC: Mekanistic Therapeutics, LLC            Topic: NCI

    PROJECT SUMMARY Mekanistic Therapeutics seeks to design discover and develop anti cancer agents that selectively inhibit multiple oncogenic pathways Its lead agent MTX was discovered in collaboration with the Leopold laboratory at University of Michigan MTX is a novel kinase inhibitor showing early promise for its therapeutic potential against solid cancers refractory to current treatm ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Commercial Software Using High throughput Computational Techniques to Improve Genome Analysis

    SBC: Genomenon, Inc.            Topic: 172

    Recent advances in DNA sequencing technology have not been matched by improved analytic techniques to quickly and accurately interpret patient genome data to inform diagnosis prognosis and therapy making decisions in the clinic and to identify candidate biomarkers of disease in research laboratories Development of automated techniques to facilitate interpretation of this data will benefit patien ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. A nanoparticle delivery system for CRISPR Cas based therapeutics

    SBC: ATGC Inc.            Topic: NCATS

    Abstract Applications of customizable nucleases such as CRISPR clustered regularly interspaced short palindromic repeats Cas CRISPR associated protein have enabled efficient and precise gene correction in vitro and hold promises for eventually achieving in vivo gene correction therapy However to apply CRISPR Cas in therapeutic settings several major challenges remain to be addressed ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. HTS Assays for Targeting the cGAS STING Pathway in Autoimmune Diseases and Cancer

    SBC: Bellbrook Labs, LLC            Topic: 300

    SUMMARY Cytoplasmic nucleic acids alert the immune system to invading pathogens and trigger a robust type I interferon IFN response via activation of the STING stimulator of interferon genes receptor The sensor for cytoplasmic nucleic acids was recently discovered to be a cyclic GMP AMP synthase which produces a unique cyclic dinucleotide second messenger cGAMP that serves as an agonist fo ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Automation of MicroC as a CDx for myeloma therapies

    SBC: Lynx Biosciences, Inc.            Topic: 102

    Multiple myeloma MM is a debilitating and currently incurable hematological malignancy While the median survival has increased to years MM patients ultimately relapse and become resistant to therapy Once they reach this stage it is often a trial and error process until an effective therapy can be found Furthermore the MM bone marrow tumor microenvironment plays a significant role in ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Hormonal Therapeutic for Retinopathy of Prematurity

    SBC: Zietchick Research Institute, LLC            Topic: W

    Whenever premature birth interrupts normal retinal vascularization of the developing eye retinopathy of prematurity ROP can occur When ROP was first reported in the s it was associated with high oxygen delivery to preterm infants Though oxygen delivery to preterm infants is now carefully regulated ROP is still a common occurrence In very low birthweight infants birth weights andlt ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Fc folate Conjugate for the Treatment of Triple Negative Breast Cancer

    SBC: NeuLink Inc.            Topic: 100

    Abstract According to the American Cancer Society in women in the U S will develop breast cancer at some point in their life and of these women will have triple negative breast cancer TNBC an aggressive subtype of breast cancer that lacks the three receptors ER PR HER that current drug treatment targets tamoxifen Herceptin Because of its aggressive nature and lack of effec ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government